Risk Factors ofMultidrug-ResistantBacteria in LowerRespiratory Tract Infections: A Systematic Review and Meta-Analysis
暂无分享,去创建一个
Kailiang Xu | Gang Chen | Fangyuan Sun | B. Fang | Yuxia Sun | Ziyuan Kong
[1] Wei Zhu,et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection relative to two types of control patients: a systematic review and meta-analysis , 2020, Antimicrobial Resistance & Infection Control.
[2] Roger Williams,et al. Antimicrobial resistance in chronic liver disease , 2019, Hepatology International.
[3] M. Ip,et al. Antibiotic-Resistant Community-Acquired Bacterial Pneumonia. , 2019, Infectious disease clinics of North America.
[4] R. Wunderink,et al. Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community‐acquired pneumonia , 2019, Respirology.
[5] Tiantuo Zhang,et al. Differences in microbial etiology between hospital-acquired pneumonia and ventilator-associated pneumonia: a single-center retrospective study in Guang Zhou , 2019, Infection and drug resistance.
[6] M. Scott,et al. A nonlinear time-series analysis approach to identify thresholds in associations between population antibiotic use and rates of resistance , 2019, Nature Microbiology.
[7] H. Van Vlierberghe,et al. Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. , 2019, Gastroenterology.
[8] Zhao Zhang,et al. Molecular Epidemiology and Risk Factors of Ventilator-Associated Pneumonia Infection Caused by Carbapenem-Resistant Enterobacteriaceae , 2019, Front. Pharmacol..
[9] Eyal Oren,et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet. Infectious diseases.
[10] Mohammad Hossein Khosravi,et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.
[11] N. Bhattarai,et al. Incidence and outcomes of multidrug-resistant gram-negative bacteria infections in intensive care unit from Nepal- a prospective cohort study , 2018, Antimicrobial Resistance & Infection Control.
[12] Xuan Sun,et al. Risk factors for multidrug‐resistant Gram‐negative bacteria infection in intensive care units: A meta‐analysis , 2018, International journal of nursing practice.
[13] Yee-Chun Chen,et al. Risk for subsequent infection and mortality after hospitalization among patients with multidrug-resistant gram-negative bacteria colonization or infection , 2018, Antimicrobial Resistance & Infection Control.
[14] Ying Luan,et al. Pathogenic bacterial profile and drug resistance analysis of community-acquired pneumonia in older outpatients with fever , 2018, The Journal of international medical research.
[15] W. Rodriguez-Cintron,et al. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients , 2018, European Respiratory Journal.
[16] G. Raman,et al. Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis , 2018, Antimicrobial Resistance & Infection Control.
[17] W. Guan,et al. Antibiotic-resistant Pseudomonas aeruginosa infection in patients with bronchiectasis: prevalence, risk factors and prognostic implications , 2018, International journal of chronic obstructive pulmonary disease.
[18] Hyung Koo Kang,et al. Proposed risk factors for infection with multidrug-resistant pathogens in hemodialysis patients hospitalized with pneumonia , 2017, BMC Infectious Diseases.
[19] P. Ji,et al. Trends and relationship between antimicrobial resistance and antibiotic use in Xinjiang Uyghur Autonomous Region, China: Based on a 3 year surveillance data, 2014-2016. , 2017, Journal of infection and public health.
[20] E. Snitkin,et al. Network of microbial and antibiotic interactions drive colonization and infection with multidrug-resistant organisms , 2017, Proceedings of the National Academy of Sciences.
[21] M. Samore,et al. Attributable Mortality of Healthcare-Associated Infections Due to Multidrug-Resistant Gram-Negative Bacteria and Methicillin-Resistant Staphylococcus Aureus , 2017, Infection Control & Hospital Epidemiology.
[22] Ziwen Zhao,et al. Pneumonia caused by extensive drug-resistant Acinetobacter baumannii among hospitalized patients: genetic relationships, risk factors and mortality , 2017, BMC Infectious Diseases.
[23] A. Torres,et al. Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance. , 2017, The Journal of infection.
[24] M. Bassetti,et al. The management of multidrug-resistant Enterobacteriaceae , 2016, Current opinion in infectious diseases.
[25] B. Kocić,et al. Correlation between antimicrobial consumption and antimicrobial resistance of Pseudomonas aeruginosa in a hospital setting: a 10‐year study , 2016, Journal of clinical pharmacy and therapeutics.
[26] G. Guyatt,et al. Prognosis after surgical replacement with a bioprosthetic aortic valve in patients with severe symptomatic aortic stenosis: systematic review of observational studies , 2016, British Medical Journal.
[27] Jung-San Chang,et al. An antibiotic decision-making tool for patients with pneumonia admitted to a medical intensive care unit. , 2016, International journal of antimicrobial agents.
[28] Peggy Cruse,et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] Tim Friede,et al. Meta‐analysis of two studies in the presence of heterogeneity with applications in rare diseases , 2016, Biometrical journal. Biometrische Zeitschrift.
[30] Marcus D. Ruopp,et al. Respiratory Tract Infection Clinical Trials from 2007 to 2012. A Systematic Review of ClinicalTrials.gov. , 2015, Annals of the American Thoracic Society.
[31] A. Großhennig,et al. No solution yet for combining two independent studies in the presence of heterogeneity , 2015, Statistics in medicine.
[32] Z. Memish,et al. Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options , 2014, Lancet. Infectious Diseases (Print).
[33] T. V. Van Schooneveld,et al. Epidemiology and Predictors of Multidrug-Resistant Community-Acquired and Health Care-Associated Pneumonia , 2014, Antimicrobial Agents and Chemotherapy.
[34] George F Borm,et al. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method , 2014, BMC Medical Research Methodology.
[35] A. Kaya,et al. Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: risk factors, clinical features, and outcomes. , 2014, American journal of infection control.
[36] Jian-hui Chen,et al. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia. , 2013, American journal of infection control.
[37] Hong-tao Xu,et al. Prevalence and clinical prognosis of heteroresistant vancomycin-intermediate Staphylococcus aureus in a tertiary care center in China. , 2013, Chinese medical journal.
[38] A. Costa-Pereira,et al. Additional risk factors for infection by multidrug-resistant pathogens in healthcare-associated infection: a large cohort study , 2012, BMC Infectious Diseases.
[39] A. Péchinot,et al. Candida spp. airway colonization could promote antibiotic-resistant bacteria selection in patients with suspected ventilator-associated pneumonia , 2012, Intensive Care Medicine.
[40] M. Falagas,et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[41] W. Wang,et al. Risk factors for pneumonia caused by multidrug‐resistant Gram‐negative bacilli among liver recipients , 2010, Clinical transplantation.
[42] M. J. Pozuelo,et al. Chronic colonization by Pseudomonas aeruginosa of patients with obstructive lung diseases: cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. , 2010, Diagnostic microbiology and infectious disease.
[43] J. Ioannidis,et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Journal of clinical epidemiology.
[44] M. Maciá,et al. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[45] Maarten Bekaert,et al. Determinants and impact of multidrug antibiotic resistance in pathogens causing ventilator-associated-pneumonia , 2008, Critical care.
[46] 古谷 良輔,et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.
[47] S. Nseir,et al. Prevalence and outcome of severe chronic obstructive pulmonary disease exacerbations caused by multidrug-resistant bacteria , 2008, Current opinion in pulmonary medicine.
[48] Jill Hayden,et al. Evaluation of the Quality of Prognosis Studies in Systematic Reviews , 2006, Annals of Internal Medicine.
[49] P. Hsueh,et al. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991–2003 at a university hospital in Taiwan , 2005, International Journal of Antimicrobial Agents.
[50] D. Gu,et al. A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study. , 2018, The Lancet. Infectious diseases.
[51] Peter A. Alces,et al. Reinventing the wheel? , 2009, The Lancet. Oncology.